Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.72 |
| ▸ | DRD3 | P35462 | 13/20 | 0.72 |
| ▸ | DRD4 | P21917 | 5/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1900842 | 0.98 | DRD2 (0.70) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL2216581 | 0.91 | DRD2 (0.74) | DRD2DRD3DRD4HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL1052104 | 0.89 | DRD2 (0.72) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL3187869 | 0.89 | DRD2 (0.72) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL9347278 | 0.88 | KDM4E (0.62) | DRD2DRD3DRD4HTR1ASLC6A2 | |
| Propylamine SCHEMBL28972670 | 0.88 | DRD2 (0.89) | DRD2DRD3DRD4HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL3207609 | 0.88 | DRD2 (0.70) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL14494898 | 0.87 | DRD2 (0.67) | DRD2DRD3DRD4DRD5 | |
| SCHEMBL14494936 | 0.85 | DRD2 (0.74) | DRD2DRD3DRD4HTR2AHTR1A | |
| SCHEMBL1193545 | 0.84 | DRD2 (1.00) | DRD2DRD3DRD4HTR2ADRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-119497615-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| WO-2021241876-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | 재단법인 대구경북첨단의료산업진흥재단 | 2021-12-02 | — | — | WO | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2011059207-A2 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059207-A2 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | disclosed |
| EP-0751939-B9 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0751939-B1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0751939-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995025727-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1995-09-28 | — | — | WO | disclosed |
| US-5395835-A | Antipsychotic agents | WARNER-LAMBERT COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | NPY5R, TPH2, MC5R | DRD2 347/4885DRD3 517/4885DRD4 425/4885 |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | MAOA, DRD2, MAOB | DRD2 2/4885DRD3 14/4885DRD4 31/4885 |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | DRD2 2579/4885DRD3 2416/4885DRD4 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.